Skip to main content
Top
Published in: Hepatology International 6/2020

01-12-2020 | Hypertension | Original Article

Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension

Authors: Pierre Raeven, Joanna Baron-Stefaniak, Benedikt Simbrunner, Alexander Stadlmann, Philipp Schwabl, Bernhard Scheiner, Eva Schaden, Ernst Eigenbauer, Peter Quehenberger, Mattias Mandorfer, David Marek Baron, Thomas Reiberger

Published in: Hepatology International | Issue 6/2020

Login to get access

Abstract

Background

Rotational thromboelastometry (ROTEM) has been studied in patients with advanced chronic liver disease (ACLD) without considering the impact of portal hypertension. We evaluated the influence of the hepatic venous pressure gradient (HVPG) on ROTEM results in patients with ACLD.

Methods

Cross-sectional study; ACLD patients undergoing HVPG measurement within the prospective Vienna Cirrhosis Study (NCT03267615) underwent concomitant ROTEM testing.

Results

Among 159 patients (68% male; Child–Pugh-A: 53%, Child–Pugh-B: 34%, Child–Pugh-C: 13%), 21 patients (13%) had a HVPG between 6 and 10 mmHg, 84 patients (53%) between 10 and 19 mmHg, and 54 patients (34%) ≥ 20 mmHg. Child–Pugh-C patients (vs. Child–Pugh-A and vs. Child–Pugh-B patients, respectively) showed longer clot formation time (CFT: median 187 s vs. 122 s vs. 122 s, p = 0.007) and lower maximum clot firmness (MCF: median: 45 mm vs. 56 mm vs. 56 mm, p = 0.002) in extrinsic thromboelastometry (EXTEM), while platelet counts were similar across Child–Pugh stages. In the overall cohort, ROTEM parameters did not differ by severity of portal hypertension. However, among compensated Child–Pugh-A patients, MCF decreased with increasing portal pressure, i.e. in higher HVPG strata (HVPG 9–10 mmHg: median MCF: 59 mm vs. HVPG 10–19 mmHg: 56 mm vs HVPG ≥ 20 mmHg: 54 mm, p = 0.023). Furthermore, patients with short CFT and high MCF in EXTEM had higher levels of lipopolysaccharide-binding protein, C-reactive protein, and procalcitonin, as well as higher leukocyte counts (all p < 0.05).

Conclusions

Portal hypertension seems to impact ROTEM results only in compensated Child–Pugh-A patients. Bacterial translocation and systemic inflammation may trigger a procoagulant state in patients with ACLD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365(2):147–156CrossRef Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365(2):147–156CrossRef
2.
go back to reference Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010;116(6):878–885CrossRef Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010;116(6):878–885CrossRef
3.
go back to reference Scheiner B, Northup PG, Gruber AB, Semmler G, Leitner G, Quehenberger P, et al. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Liver Int 2020;40(6):1415–1426CrossRef Scheiner B, Northup PG, Gruber AB, Semmler G, Leitner G, Quehenberger P, et al. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Liver Int 2020;40(6):1415–1426CrossRef
5.
go back to reference Dumitrescu G, Januszkiewicz A, Agren A, Magnusson M, Wahlin S, Wernerman J. Thromboelastometry: relation to the severity of liver cirrhosis in patients considered for liver transplantation. Medicine (Baltimore) 2017;96(23):e7101CrossRef Dumitrescu G, Januszkiewicz A, Agren A, Magnusson M, Wahlin S, Wernerman J. Thromboelastometry: relation to the severity of liver cirrhosis in patients considered for liver transplantation. Medicine (Baltimore) 2017;96(23):e7101CrossRef
6.
go back to reference Hugenholtz GCG, Lisman T, Stravitz RT. Thromboelastography does not predict outcome in different etiologies of cirrhosis. Res Pract Thromb Haemost 2017;1(2):275–285CrossRef Hugenholtz GCG, Lisman T, Stravitz RT. Thromboelastography does not predict outcome in different etiologies of cirrhosis. Res Pract Thromb Haemost 2017;1(2):275–285CrossRef
7.
go back to reference Kleinegris MC, Bos MH, Roest M, Henskens Y, Ten Cate-Hoek A, Van Deursen C, et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost 2014;12(10):1647–1657CrossRef Kleinegris MC, Bos MH, Roest M, Henskens Y, Ten Cate-Hoek A, Van Deursen C, et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost 2014;12(10):1647–1657CrossRef
8.
go back to reference Lentschener C, Flaujac C, Ibrahim F, Gouin-Thibault I, Bazin M, Sogni P, et al. Assessment of haemostasis in patients with cirrhosis: relevance of the ROTEM tests? A prospective, cross-sectional study. Eur J Anaesthesiol 2016;33(2):126–133CrossRef Lentschener C, Flaujac C, Ibrahim F, Gouin-Thibault I, Bazin M, Sogni P, et al. Assessment of haemostasis in patients with cirrhosis: relevance of the ROTEM tests? A prospective, cross-sectional study. Eur J Anaesthesiol 2016;33(2):126–133CrossRef
9.
go back to reference Stegewerth K, Weber CF, Moehlmann M, Adam EH, Zacharowski K, Zeuzem S, et al. Fast interpretation of thromboelastometry and aggregometry in patients suffering from chronic liver disease. Clin Lab 2019;65(8) Stegewerth K, Weber CF, Moehlmann M, Adam EH, Zacharowski K, Zeuzem S, et al. Fast interpretation of thromboelastometry and aggregometry in patients suffering from chronic liver disease. Clin Lab 2019;65(8)
10.
go back to reference Tripodi A, Primignani M, Chantarangkul V, Viscardi Y, Dell’Era A, Fabris FM, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009;124(1):132–136CrossRef Tripodi A, Primignani M, Chantarangkul V, Viscardi Y, Dell’Era A, Fabris FM, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009;124(1):132–136CrossRef
11.
go back to reference de Franchis R, VIF B. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63(3):743–752 de Franchis R, VIF B. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63(3):743–752
12.
go back to reference Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133(2):481–488CrossRef Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133(2):481–488CrossRef
13.
go back to reference Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stattermayer AF, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology 2019 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stattermayer AF, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology 2019
14.
go back to reference D’Amico G, Pasta L, Morabito A, D’Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014;39(10):1180–1193CrossRef D’Amico G, Pasta L, Morabito A, D’Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014;39(10):1180–1193CrossRef
15.
go back to reference Reiberger T, Puspok A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129(Suppl 3):135–158CrossRef Reiberger T, Puspok A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129(Suppl 3):135–158CrossRef
16.
go back to reference Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117(3):626–631CrossRef Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117(3):626–631CrossRef
17.
go back to reference Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013;58(5):911–921CrossRef Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013;58(5):911–921CrossRef
18.
go back to reference Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019;25(39):5897–5917CrossRef Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019;25(39):5897–5917CrossRef
19.
go back to reference Wosiewicz P, Zorniak M, Hartleb M, Baranski K, Hartleb M, Onyszczuk M, et al. Portal vein thrombosis in cirrhosis is not associated with intestinal barrier disruption or increased platelet aggregability. Clin Res Hepatol Gastroenterol 2016;40(6):722–729CrossRef Wosiewicz P, Zorniak M, Hartleb M, Baranski K, Hartleb M, Onyszczuk M, et al. Portal vein thrombosis in cirrhosis is not associated with intestinal barrier disruption or increased platelet aggregability. Clin Res Hepatol Gastroenterol 2016;40(6):722–729CrossRef
20.
go back to reference Payance A, Bissonnette J, Roux O, Elkrief L, Gault N, Francoz C, et al. Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis. Aliment Pharmacol Ther 2016;43(9):966–973CrossRef Payance A, Bissonnette J, Roux O, Elkrief L, Gault N, Francoz C, et al. Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis. Aliment Pharmacol Ther 2016;43(9):966–973CrossRef
21.
go back to reference Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. J Vis Exp 2020(160) Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. J Vis Exp 2020(160)
22.
go back to reference D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. J Hepatol 2018;68(3):563–576CrossRef D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. J Hepatol 2018;68(3):563–576CrossRef
23.
go back to reference Turco L, de Raucourt E, Valla D, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep 2019;1(3):227–239CrossRef Turco L, de Raucourt E, Valla D, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep 2019;1(3):227–239CrossRef
24.
go back to reference Jindal A, Bhardwaj A, Kumar G, Sarin SK. Clinical decompensation and outcomes in patients with compensated cirrhosis and a hepatic venous pressure gradient >/=20 mm Hg. Am J Gastroenterol 2020 Jindal A, Bhardwaj A, Kumar G, Sarin SK. Clinical decompensation and outcomes in patients with compensated cirrhosis and a hepatic venous pressure gradient >/=20 mm Hg. Am J Gastroenterol 2020
25.
go back to reference Mandorfer M, Hernandez-Gea V, Garcia-Pagan JC, Reiberger T. Noninvasive diagnostics for portal hypertension: a comprehensive review. Semin Liver Dis 2020 Mandorfer M, Hernandez-Gea V, Garcia-Pagan JC, Reiberger T. Noninvasive diagnostics for portal hypertension: a comprehensive review. Semin Liver Dis 2020
26.
go back to reference Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998;43(2):267–271CrossRef Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998;43(2):267–271CrossRef
27.
go back to reference Debernardi Venon W, Ponzo P, Sacco M, Mengozzi G, Raso S, Valpreda A, et al. Usefulness of thromboelastometry in predicting the risk of bleeding in cirrhotics who undergo invasive procedures. Eur J Gastroenterol Hepatol 2015;27(11):1313–1319CrossRef Debernardi Venon W, Ponzo P, Sacco M, Mengozzi G, Raso S, Valpreda A, et al. Usefulness of thromboelastometry in predicting the risk of bleeding in cirrhotics who undergo invasive procedures. Eur J Gastroenterol Hepatol 2015;27(11):1313–1319CrossRef
28.
go back to reference Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther 2018;47(7):980–988CrossRef Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther 2018;47(7):980–988CrossRef
29.
go back to reference Bos S, van den Boom B, Kamphuisen PW, Adelmeijer J, Blokzijl H, Schreuder T, et al. Haemostatic profiles are similar across all aetiologies of cirrhosis. Thromb Haemost 2019;119(2):246–253CrossRef Bos S, van den Boom B, Kamphuisen PW, Adelmeijer J, Blokzijl H, Schreuder T, et al. Haemostatic profiles are similar across all aetiologies of cirrhosis. Thromb Haemost 2019;119(2):246–253CrossRef
30.
go back to reference Bianchini M, De Pietri L, Villa E. Coagulopathy in liver diseases: complication or therapy? Dig Dis 2014;32(5):609–614CrossRef Bianchini M, De Pietri L, Villa E. Coagulopathy in liver diseases: complication or therapy? Dig Dis 2014;32(5):609–614CrossRef
Metadata
Title
Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
Authors
Pierre Raeven
Joanna Baron-Stefaniak
Benedikt Simbrunner
Alexander Stadlmann
Philipp Schwabl
Bernhard Scheiner
Eva Schaden
Ernst Eigenbauer
Peter Quehenberger
Mattias Mandorfer
David Marek Baron
Thomas Reiberger
Publication date
01-12-2020
Publisher
Springer India
Published in
Hepatology International / Issue 6/2020
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-020-10093-3

Other articles of this Issue 6/2020

Hepatology International 6/2020 Go to the issue